Contents
Current Neuropharmacology, Volume 14 - Number 3
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
, 14(3): 214 - 225Jean-Marc Taymans and Elisa Greggio
DOI: 10.2174/1570159X13666151030102847
Modulating the Amyloidogenesis of α-Synuclein
, 14(3): 226 - 237Kalkena Sivanesam and Niels H. Andersen
DOI: 10.2174/1570159X13666151030103153
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
, 14(3): 238 - 249Pilar Rivero-Ríos, Jesús Madero-Pérez,, Belén Fernández and Sabine Hilfiker
DOI: 10.2174/1570159X13666151030103027
Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
, 14(3): 250 - 259Alice Nardin, Emilie Schrepfer and Elena Ziviani
DOI: 10.2174/1570159X13666151030104414
Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
, 14(3): 260 - 271Roberta Filograna, Mariano Beltramini, Luigi Bubacco and Marco Bisaglia
DOI: 10.2174/1570159X13666151030102718
Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
, 14(3): 272 - 281Chi-Hsien Huang, Chia-Chen Huang, Cheuk-Kwan Sun, Gong-Hong Lin and Wen-Hsuan Hou
DOI: 10.2174/1570159X13666150514233033
Selenium in the Therapy of Neurological Diseases. Where is it Going?
, 14(3): 282 - 299Agnieszka Dominiak, Anna Wilkaniec, Piotr Wroczyński and Agata Adamczyk
DOI: 10.2174/1570159X14666151223100011
Webmaster Contact: info@benthamscience.org